Fig. 2: Reduction of brain miR-195 levels in human brain and CSF samples is associated with ApoE4 genotype, disease progression, and cognitive decline. | Molecular Psychiatry

Fig. 2: Reduction of brain miR-195 levels in human brain and CSF samples is associated with ApoE4 genotype, disease progression, and cognitive decline.

From: MicroRNA-195 rescues ApoE4-induced cognitive deficits and lysosomal defects in Alzheimer’s disease pathogenesis

Fig. 2

a Amounts of miR-195 (presented as Log2 fold changes) in human parietal cortex tissue of ApoE4+/− subjects (CDR0.5-1) were lower than those in ApoE4−/− subjects. N = 17–18/group; log2FC fold of changes: ApoE4−/− 0.054 ± 0.113 versus ApoE4+/− −0.570 ± 0.178, **p < 0.01 with independent-samples t-tests. b Pattern of reduction in miR-195 levels (presented as Log2 fold changes) along with AD disease progression from normal aging to MCI and early AD. N = 12–19/group; log2FC: 1.626 ± 0.696 in CDR 0 subjects versus 0.242 ± 0.104 in CDR 0.5 MCI patients; versus −0.663 ± 0.135 in CDR 1 AD subjects; *p < 0.05, ****p < 0.0001 with ANOVA tests. c Positive correlation between CSF miR-195 levels and MMSE scores (r = 0.455, p = 0.029; N = 23). d Negative correlation between CSF miR-195 and pTau levels (r = −0.408, p = 0.04; N = 23).

Back to article page